Huddinge-based Sprint Bioscience has had an eventful 2021 to say the least. In the face of the success of the past year, the company is now taking concrete steps to be able to increase the pace even further. The goal for the company is to broaden its portfolio of preclinical drug programmes in cancer and increase the number of programmes licensed to partners, thus increasing the potential for multiple revenue streams.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
